Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice
Phillip Pymm, Amy Adair, Li‐Jin Chan, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 19
Open Access | Times Cited: 143

Showing 1-25 of 143 citing articles:

Optimal Control of the COVID-19 Pandemic with Non-pharmaceutical Interventions
T. Alex Perkins, Guido España
Bulletin of Mathematical Biology (2020) Vol. 82, Iss. 9
Open Access | Times Cited: 179
Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies
Yifan Wang, Caixuan Liu, Chao Zhang, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 158
A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19
Jiandong Huo, Halina Mikolajek, Audrey Le Bas, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 131
A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo
Leo Hanke, Hrishikesh Das, Daniel J. Sheward, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 73
The success of SARS-CoV-2 vaccines and challenges ahead
Kanta Subbarao
Cell Host & Microbe (2021) Vol. 29, Iss. 7, pp. 1111-1123
Open Access | Times Cited: 90
Neutralization of SARS‐CoV‐2 by highly potent, hyperthermostable, and mutation‐tolerant nanobodies
Thomas Güttler, Metin Aksu, Antje Dickmanns, et al.
The EMBO Journal (2021) Vol. 40, Iss. 19
Open Access | Times Cited: 90
CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma
Jiejie Geng, Liang Chen, Yufeng Yuan, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 86
A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration
Xilin Wu, Lin Cheng, Ming Fu, et al.
Cell Reports (2021) Vol. 37, Iss. 3, pp. 109869-109869
Open Access | Times Cited: 84
Effect of early application of social distancing interventions on COVID-19 mortality over the first pandemic wave: An analysis of longitudinal data from 37 countries
Daniele Piovani, Maria Nefeli Christodoulou, Andreas Hadjidemetriou, et al.
Journal of Infection (2020) Vol. 82, Iss. 1, pp. 133-142
Open Access | Times Cited: 80
Early analysis of the Australian COVID-19 epidemic
David J. Price, Freya M. Shearer, Michael T. Meehan, et al.
eLife (2020) Vol. 9
Open Access | Times Cited: 77
Recent advances in management of COVID-19: A review
Soraya Mouffak, Qamar Shubbar, Ekram Saleh, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 143, pp. 112107-112107
Open Access | Times Cited: 76
NanoNet: Rapid and accurate end-to-end nanobody modeling by deep learning
Tomer Cohen, Matan Halfon, Dina Schneidman‐Duhovny
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 70
Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape
Fred D. Mast, Peter C. Fridy, Natalia E. Ketaren, et al.
eLife (2021) Vol. 10
Open Access | Times Cited: 58
SARS-CoV-2 Antiviral Therapy
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Clinical Microbiology Reviews (2021) Vol. 34, Iss. 4
Open Access | Times Cited: 57
Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses
Mingxi Li, Yifei Ren, Zhen Qin Aw, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 55
Impact of new variants on SARS-CoV-2 infectivity and neutralization: A molecular assessment of the alterations in the spike-host protein interactions
Mary Hongying Cheng, James Krieger, Anupam Banerjee, et al.
iScience (2022) Vol. 25, Iss. 3, pp. 103939-103939
Open Access | Times Cited: 47
Advances in Nanomaterial-Based Platforms to Combat COVID-19: Diagnostics, Preventions, Therapeutics, and Vaccine Developments
Niaz Mahmud, Muzahidul I. Anik, M. Khalid Hossain, et al.
ACS Applied Bio Materials (2022) Vol. 5, Iss. 6, pp. 2431-2460
Closed Access | Times Cited: 46
Biparatopic sybodies neutralize SARS‐CoV‐2 variants of concern and mitigate drug resistance
Justin D. Walter, Melanie Scherer, Cedric A. J. Hutter, et al.
EMBO Reports (2022) Vol. 23, Iss. 4
Open Access | Times Cited: 40
Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity
Wei‐Hung Chen, Agnes Hajduczki, Elizabeth J. Martinez, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 27
Nanobodies: a promising approach to treatment of viral diseases
Vitória Meneghetti Minatel, Carlos Roberto Prudêncio, Benedito Barraviera, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 9
Nanoscale warriors against viral invaders: a comprehensive review of Nanobodies as potential antiviral therapeutics
Vaishali Verma, N. D. Sinha, A. Raja
mAbs (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 1
Early Warnings: The Lessons of COVID-19 for Public Health Climate Preparedness
Mary C. Sheehan, Mary A. Fox
International Journal of Health Services (2020) Vol. 50, Iss. 3, pp. 264-270
Open Access | Times Cited: 62
The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates
Gang Ye, Joseph P. Gallant, Jian Zheng, et al.
eLife (2021) Vol. 10
Open Access | Times Cited: 55
An affinity-enhanced, broadly neutralizing heavy chain–only antibody protects against SARS-CoV-2 infection in animal models
Bert Schepens, Loes van Schie, Wim Nerinckx, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 621
Open Access | Times Cited: 55
COVID-19 Diagnosis: Current and Future Techniques
Aarjoo Sharma, Sanjeev Balda, Mansi Apreja, et al.
International Journal of Biological Macromolecules (2021) Vol. 193, pp. 1835-1844
Open Access | Times Cited: 55
Page 1 - Next Page

Scroll to top